Allianz Asset Management GmbH Takes Position in Bruker Corporation (NASDAQ:BRKR)

Key Points

• Allianz Asset Management GmbH has invested approximately $363,000 in Bruker Corporation by acquiring 8,695 shares, as reported in its latest SEC filing.
• Bruker reported $801.4 million in revenue for the most recent quarter, exceeding analyst estimates, alongside an EPS of $0.47, slightly above the consensus of $0.46.
• Major institutional investors have significantly increased their stakes in Bruker, with ownership by hedge funds now comprising 79.52% of the company.

Allianz Asset Management GmbH purchased a new position in Bruker Corporation (NASDAQ:BRKR - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 8,695 shares of the medical research company's stock, valued at approximately $363,000.

Other hedge funds have also recently made changes to their positions in the company. London Co. of Virginia raised its position in shares of Bruker by 78.4% in the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock valued at $245,820,000 after purchasing an additional 1,843,294 shares during the period. Sculptor Capital LP raised its holdings in Bruker by 484.1% during the 4th quarter. Sculptor Capital LP now owns 1,714,015 shares of the medical research company's stock valued at $100,476,000 after acquiring an additional 1,420,569 shares during the period. FIL Ltd raised its stake in shares of Bruker by 262.3% during the 4th quarter. FIL Ltd now owns 1,961,416 shares of the medical research company's stock valued at $114,978,000 after purchasing an additional 1,420,102 shares during the period. Steadfast Capital Management LP bought a new stake in shares of Bruker during the 4th quarter valued at $63,997,000. Finally, Marshall Wace LLP increased its position in shares of Bruker by 4,510.3% during the fourth quarter. Marshall Wace LLP now owns 783,988 shares of the medical research company's stock valued at $45,957,000 after buying an additional 766,983 shares during the period. 79.52% of the stock is currently owned by institutional investors.

Bruker Trading Down 8.6%

Shares of Bruker stock traded down $3.27 on Monday, hitting $34.72. The stock had a trading volume of 8,149,176 shares, compared to its average volume of 2,385,735. The company has a quick ratio of 0.74, a current ratio of 1.57 and a debt-to-equity ratio of 1.13. Bruker Corporation has a one year low of $32.07 and a one year high of $72.94. The stock has a market cap of $5.26 billion, a price-to-earnings ratio of 66.77, a PEG ratio of 2.56 and a beta of 1.16. The stock's 50-day simple moving average is $39.94 and its two-hundred day simple moving average is $43.35.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.11). The business had revenue of $797.40 million during the quarter, compared to the consensus estimate of $811.17 million. Bruker had a return on equity of 19.47% and a net margin of 2.31%. The firm's revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.52 earnings per share. As a group, sell-side analysts predict that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Monday, June 16th were issued a $0.05 dividend. The ex-dividend date was Monday, June 16th. This represents a $0.20 annualized dividend and a yield of 0.6%. Bruker's payout ratio is 38.46%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Citigroup decreased their target price on shares of Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a report on Monday. UBS Group decreased their price target on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Barclays decreased their target price on Bruker from $46.00 to $43.00 and set an "overweight" rating on the stock in a research note on Monday. Bank of America decreased their price objective on shares of Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. Finally, The Goldman Sachs Group decreased their price target on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $53.10.

Insiders Place Their Bets

In related news, CEO Frank H. Laukien purchased 2,608 shares of the business's stock in a transaction that occurred on Friday, June 6th. The shares were acquired at an average price of $38.36 per share, for a total transaction of $100,042.88. Following the completion of the acquisition, the chief executive officer directly owned 38,462,171 shares in the company, valued at approximately $1,475,408,879.56. The trade was a 0.01% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 27.30% of the stock is currently owned by company insiders.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.